Engineered bacteriophage targeting gene networks as adjuvants for antibiotic therapy

Antimicrobial drug development is increasingly lagging behind the evolution of antibiotic resistance, and as a result, there is a pressing need for new antibacterial therapies that can be readily designed and implemented. In this work, we engineered bacteriophage to overexpress proteins and attack gene networks that are not directly targeted by antibiotics. We show that suppressing the SOS network in Escherichia coli with engineered bacteriophage enhances killing by quinolones by several orders of magnitude in vitro and significantly increases survival of infected mice in vivo. In addition, we demonstrate that engineered bacteriophage can enhance the killing of antibiotic-resistant bacteria, persister cells, and biofilm cells, reduce the number of antibiotic-resistant bacteria that arise from an antibiotic-treated population, and act as a strong adjuvant for other bactericidal antibiotics (e.g., aminoglycosides and β-lactams). Furthermore, we show that engineering bacteriophage to target non-SOS gene networks and to overexpress multiple factors also can produce effective antibiotic adjuvants. This work establishes a synthetic biology platform for the rapid translation and integration of identified targets into effective antibiotic adjuvants.

[1]  James J. Collins,et al.  Dispersing biofilms with engineered enzymatic bacteriophage , 2007, Proceedings of the National Academy of Sciences.

[2]  B. Demple,et al.  Redox Signal Transduction: Mutations Shifting [2Fe-2S] Centers of the SoxR Sensor-Regulator to the Oxidized Form , 1997, Cell.

[3]  C. Merril,et al.  The prospect for bacteriophage therapy in Western medicine , 2003, Nature Reviews Drug Discovery.

[4]  Nicholas J. Guido,et al.  A bottom-up approach to gene regulation , 2006, Nature.

[5]  D. Endy,et al.  Refactoring bacteriophage T7 , 2005, Molecular systems biology.

[6]  R. Wise.  The relentless rise of resistance? , 2004, The Journal of antimicrobial chemotherapy.

[7]  J. Smith,et al.  4-quinolones and the SOS response. , 1989, Journal of medical microbiology.

[8]  J. W. Little,et al.  Identification of the lexA gene product of Escherichia coli K-12. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[9]  S. Leibler,et al.  Bacterial Persistence as a Phenotypic Switch , 2004, Science.

[10]  Stanley N Cohen,et al.  SOS Response Induction by ß-Lactams and Bacterial Defense Against Antibiotic Lethality , 2004, Science.

[11]  J. Heitman,et al.  Phage Trojan horses: a conditional expression system for lethal genes. , 1989, Gene.

[12]  Ron Weiss,et al.  Engineering life: building a fab for biology. , 2006, Scientific American.

[13]  James J. Collins,et al.  A Tunable Genetic Switch Based on RNAi and Repressor Proteins for Regulating Gene Expression in Mammalian Cells , 2007, Cell.

[14]  Thomas D. Schneider,et al.  OxyR and SoxRS Regulation offur , 1999, Journal of bacteriology.

[15]  J. Collins,et al.  Mistranslation of Membrane Proteins and Two-Component System Activation Trigger Antibiotic-Mediated Cell Death , 2008, Cell.

[16]  Ehud Shapiro,et al.  Tapping the computing power of biological molecules gives rise to tiny machines that can speak directly to living cells. , 2006, Scientific American.

[17]  Christopher A. Voigt,et al.  Environmentally controlled invasion of cancer cells by engineered bacteria. , 2006, Journal of molecular biology.

[18]  Gregory Stephanopoulos,et al.  A linguistic model for the rational design of antimicrobial peptides , 2006, Nature.

[19]  H. Bujard,et al.  Independent and tight regulation of transcriptional units in Escherichia coli via the LacR/O, the TetR/O and AraC/I1-I2 regulatory elements. , 1997, Nucleic acids research.

[20]  Boris Hayete,et al.  Gyrase inhibitors induce an oxidative damage cellular death pathway in Escherichia coli , 2007 .

[21]  G. Walker.  Mutagenesis and inducible responses to deoxyribonucleic acid damage in Escherichia coli. , 1984, Microbiological reviews.

[22]  U. Bläsi,et al.  Augmentation of the antimicrobial efficacy of antibiotics by filamentous phage. , 2006, Microbial drug resistance.

[23]  Paul Stoodley,et al.  Bacterial biofilms: from the Natural environment to infectious diseases , 2004, Nature Reviews Microbiology.

[24]  U. Bläsi,et al.  Therapy of Experimental Pseudomonas Infections with a Nonreplicating Genetically Modified Phage , 2004, Antimicrobial Agents and Chemotherapy.

[25]  Ehud Shapiro,et al.  Bringing DNA computers to life , 2006 .

[26]  G. Poźniak,et al.  Preparation of endotoxin-free bacteriophages. , 2004, Cellular & molecular biology letters.

[27]  C. Merril,et al.  Long-circulating bacteriophage as antibacterial agents. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[28]  S Bonhoeffer,et al.  Evaluating treatment protocols to prevent antibiotic resistance. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[29]  A. Fauci,et al.  The challenge of emerging and re-emerging infectious diseases , 2004, Nature.

[30]  U. Bläsi,et al.  Genetically modified filamentous phage as bactericidal agents: a pilot study , 2003, Letters in applied microbiology.

[31]  Floyd E Romesberg,et al.  Open access, freely available online PLoS BIOLOGY Inhibition of Mutation and Combating the Evolution of Antibiotic Resistance , 2022 .

[32]  S. Mitsuhashi,et al.  Differences in susceptibility to quinolones of outer membrane mutants of Salmonella typhimurium and Escherichia coli , 1986, Antimicrobial Agents and Chemotherapy.

[33]  J. Costerton,et al.  Antibiotic resistance of bacteria in biofilms , 2001, The Lancet.

[34]  B. Weiss,et al.  SoxR, a [2Fe-2S] transcription factor, is active only in its oxidized form. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[35]  H. Brüssow,et al.  Phage therapy: the Escherichia coli experience. , 2005, Microbiology.

[36]  Fredrik H. Karlsson,et al.  Genome-wide comparison of phage M13-infected vs. uninfected Escherichia coli. , 2005, Canadian journal of microbiology.

[37]  J. Collins,et al.  A Common Mechanism of Cellular Death Induced by Bactericidal Antibiotics , 2007, Cell.

[38]  C. Walsh.  Opinion — anti-infectives: Where will new antibiotics come from? , 2003, Nature Reviews Microbiology.

[39]  R. Schleif.  Fine-structure deletion map of the Escherichia coli L-arabinose operon. , 1972, Proceedings of the National Academy of Sciences of the United States of America.

[40]  J. Elson,et al.  Strong Purifying Selection in Transmission of Mammalian Mitochondrial DNA , 2008, PLoS biology.

[41]  Jeff Hasty,et al.  Engineered gene circuits , 2002, Nature.

[42]  R. Weiss,et al.  Advances in synthetic biology: on the path from prototypes to applications. , 2005, Current opinion in biotechnology.

[43]  J. Dolan,et al.  Use of Genetically Engineered Phage To Deliver Antimicrobial Agents to Bacteria: an Alternative Therapy for Treatment of Bacterial Infections , 2003, Antimicrobial Agents and Chemotherapy.

[44]  K. Lewis.  Persister cells, dormancy and infectious disease , 2007, Nature Reviews Microbiology.

[45]  B. Demple,et al.  The redox‐regulated SoxR protein acts from a single DNA site as a repressor and an allosteric activator , 1998, The EMBO journal.

[46]  E. Andrianantoandro,et al.  Synthetic biology: new engineering rules for an emerging discipline , 2006, Molecular systems biology.

[47]  Timothy S. Ham,et al.  Production of the antimalarial drug precursor artemisinic acid in engineered yeast , 2006, Nature.

[48]  F. Baquero,et al.  Mutation Frequencies and Antibiotic Resistance , 2000, Antimicrobial Agents and Chemotherapy.

[49]  J. J. Farmer,et al.  Phage typing of Salmonella enteritidis in the United States , 1991, Journal of clinical microbiology.

[50]  T. Romeo,et al.  Biofilm Formation and Dispersal under the Influence of the Global Regulator CsrA of Escherichia coli , 2002, Journal of bacteriology.

[51]  Barry G. Hall,et al.  Predicting the evolution of antibiotic resistance genes , 2004, Nature Reviews Microbiology.

[52]  R. Kishony,et al.  Antibiotic interactions that select against resistance , 2007, Nature.

[53]  S. Levy,et al.  Antibacterial resistance worldwide: causes, challenges and responses , 2004, Nature Medicine.

[54]  C. Yanisch-Perron,et al.  Improved M13 phage cloning vectors and host strains: nucleotide sequences of the M13mp18 and pUC19 vectors. , 1985, Gene.